Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT03895918 Completed - Malignant Neoplasm Clinical Trials

Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients

Start date: January 3, 2019
Phase: N/A
Study type: Interventional

This trial studies how well a parenting skills intervention works in improving medication adherence in pediatric cancer patients. The parenting skills intervention provides support and skills training to parents who administer medicine daily to their child and may improve the childs taking of medications correctly as prescribed by the doctor. Ultimately, this may improve treatment outcomes, among children who are experiencing an illness.

NCT ID: NCT03895684 Completed - Clinical trials for Advanced Solid Tumors

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

Start date: June 25, 2019
Phase: Phase 1
Study type: Interventional

Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.

NCT ID: NCT03895502 Completed - Neoplasms Clinical Trials

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

ONCO DVT
Start date: May 27, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.

NCT ID: NCT03894540 Terminated - Solid Tumor Clinical Trials

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Start date: March 22, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).

NCT ID: NCT03894150 Completed - Clinical trials for Refractory or Recurrent CD30+ Hematologic Malignancies

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Start date: April 11, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I dose escalation study designed to define the maximum tolerable dose(MDT), the safety profile, pharmacokinetic parameters, immunogenicity and anti-tumor activity of F0002-ADC in Chinese patients with relapsed/refractory CD30-positive hematologic malignancies.

NCT ID: NCT03893955 Active, not recruiting - Cancer Clinical Trials

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: May 21, 2019
Phase: Phase 1
Study type: Interventional

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

NCT ID: NCT03892967 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial

Start date: March 28, 2019
Phase: N/A
Study type: Interventional

This early phase I trial investigates enhanced, electronic health record (EHR)-facilitated cancer system control. Cancer and its treatment are often associated with severe, disabling symptoms that have been causally linked to diminished survival, increased healthcare utilization, degraded quality of life, unemployment, and non-adherence to recommended cancer treatments. Collaborative case management for control of moderate or worse sleep disturbance, pain, anxiety, depression, fatigue (SPADE symptoms), and physical dysfunction among cancer survivors and patients with cancer may improve quality of life, symptom severity, and adherence to cancer treatment, and may also reduce need for acute care.

NCT ID: NCT03891784 Recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Start date: October 31, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03891706 Recruiting - Solid Tumor Clinical Trials

Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

Start date: January 8, 2019
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor . The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .

NCT ID: NCT03890640 Completed - Thoracic Neoplasm Clinical Trials

Ultrasound-assisted Thoracic Epidural Catheter Insertion

Start date: July 4, 2019
Phase: N/A
Study type: Interventional

The aim of the present study is to access the success rate of ultrasound-guided thoracic epidural catheter insertion, using fluoroscopy.